- Conditions
- Pneumococcal Infections
- Interventions
- V114, Prevnar 13™, PNEUMOVAX™23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 1,515 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 38
- States / cities
- Chinle, Arizona • Fort Defiance, Arizona • Glendale, Arizona + 34 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–60
of 60
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pneumococcal Infection
- Interventions
- V116, PCV20
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,663 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 52 more
- Conditions
- Pneumococcal Vaccines
- Interventions
- 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,015 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 25
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Hollywood, Florida + 22 more
- Conditions
- Pneumococcal Vaccines
- Interventions
- 31 valent pneumococcal conjugate vaccine, PCV20, PCV21
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,049 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Chinle, Arizona • Whiteriver, Arizona + 27 more
- Conditions
- Pneumococcal Disease
- Interventions
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 42 Days to 211 Days
- Enrollment
- 3,230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 106
- States / cities
- Bessemer, Alabama • Birmingham, Alabama • Centreville, Alabama + 75 more
- Conditions
- Pneumococcal Disease
- Interventions
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 42 Days to 98 Days
- Enrollment
- 605 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 61
- States / cities
- Fayetteville, Arkansas • Jonesboro, Arkansas • La Puente, California + 39 more
- Conditions
- Pneumonia, Pneumococcal
- Interventions
- V116, PCV15, PPSV23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 717 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Tempe, Arizona + 12 more
- Conditions
- Pneumococcal Vaccines
- Interventions
- 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 802 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 32
- States / cities
- Jonesboro, Arkansas • Madera, California • Tampa, Florida + 22 more
- Conditions
- Pneumococcal Disease
- Interventions
- 20vPnC, 13vPnC, PPSV23, Saline
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,902 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 45 more
- Conditions
- Pneumococcal Disease
- Interventions
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 42 Days to 98 Days
- Enrollment
- 2,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 23
- States / cities
- Estero, Florida • Fort Lauderdale, Florida • Fort Myers, Florida + 16 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Upadacitinib, Pneumococcal 13-valent conjugate vaccine (PCV-13)
- Drug · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 52
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 44 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,882 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more